Since glucagon-like peptide-1 (7-36) amide (7-37) (GLP-1) has been found to be a potent insulinotropic hormone, it has been postulated that glucagon stimulates insulin secretion from islet beta cells through the GLP-1 receptor. We therefore examined the effects of a GLP-1 receptor antagonist, exendin (9-39) amide, on glucagon-or GLP-l-stimulated insulin release from isolated perfused rat pancreas. When infusion of 100 nmol/1 exendin (9-39) amide was started 5 min before that of 1 nmol/1 glucagon, the stimulation of insulin release by glucagon was similar to that found in the control situation (preinfusion with vehicle alone). By contrast, when 0.3 nmol/1 GLP-1 was used in the same experimental setting, exendin (9-39) amide clearly inhibited insulin release. These results indicate that glucagon stimulates insulin release mainly through glucagon receptors but not GLP-1 receptors on islet beta cells. [Diabetologia (1995) 38: 274-276] Key words Glucagon, insulin secretion, exendin (9-39), GLP-1, pancreas perfusion.
of glucagon is less potent than that of GLP-1 in the same order [10] , leading to the hypothesis that glucagon exhibits its insulinotropic activity through GLP-1 receptors but not glucagon receptors on islet beta cells [11] . Recently, it has been shown that exendin (9-39) amide is a potent receptor antagonist of GLP-1 [12, 13] . In this study, we examined the effects of exendin (9-39) amide on GLP-1 or glucagonstimulated insulin release from isolated perfused rat pancreas in order to clarify whether or not glucagon stimulates the insulin release through its own receptor.
Materials and methods
Chemicals. Glucagon, GLP-1 (7-36) amide (GLP-1) and exendin (9-39) amide (exendin (9-39)) were synthesized by the stepwise solid-phase method using an automatic synthesizer (model 430A, Applied Biosystem, Foster City, Calif., USA), and then purified by high-performance liquid chromatography (HPLC). The purity of peptides was monitored by analytical reverse-phase HPLC on a column of Nucleosil 5C-18 (4.6 x 150 mm; GL Sciences, Tokyo, Japan) under the isocratic conditions of 0.1% trifluoroacetic acid and 39 % acetonitril, and proved to be at least 98 % pure [14] . Rat pancreas perfusion. The pancreas was isolated in male Wistar rats, weighing 300-350 g, under pentobarbital anaesthesia after an overnight fast. All rats were housed in a windowless, air-controlled room (22 + 2~ under a 12-h light (08.00-20.00) hours/12-h dark cycle, and fed standard rat chow and water ad libiturn. Perfusion was carried out according to the method of Grodsky et al. [15] . A Krebs-Ringer bicarbonate buffer solution containing 4 % dextran T-70 (Pharmacia Fine Chemicals, Uppsala, Sweden), 0.2 % bovine serum albumin (BSA), 5 mmol/1 each of pyruvate, fumarate, glutamate and arginine, and 5.5 retool/1 glucose was equilibrated with a 95 % O~-5 % CO2 mixture at 37~ and then continuously gassed throughout the experiment. The pancreas was perfused from the celiac artery at a flow rate of 2 ml/min. After 25 rain of equilibration, the effluent perfusate was collected at 1-min intervals by a cannula inserted into the portal vein. There was an initial basal period of 10 rain, and then exendin (9-39) dissolved in 0.9 % NaC1 solution containing 0.2 % BSA was administered for 15 rain through a side-arm syringe at a rate of 0.1 ml/min. Beginning 5 min later, glucagon or GLP-1 dissolved in 0.9 % NaC1 containing 0.2 % BSA, 5 mmol/1 arginine and 5.5 mmol/1 glucose was infused for 10 min through another side-arm syringe at a rate of 0.1 ml/min.
Assay. Immunoreactive insulin (IRI) was determined by RIA
according to the method of Herbert et al. [16] .
Statistical analysis
The degree of stimulation of insulin release initiated by the peptides was calculated as areas under the curve [14] and compared by Student's t-test for unpaired data. p < 0.05 was considered significant, and all data are expressed as means + SEM. Figure 1 A, 100 nmol/1 exendin (9-39) inhibited insulin release; the percent decrease in ZAIRI from the preceding basal level was 40.3 +3.6%
Results

As shown in
(n = 5), which is significantly lower than that of the control experiment (infusion of the vehicle; 0.9 % NaC1 containing 0.2% BSA, data not shown); 25.1 + 5.3 % (n --7, p < 0.01). The infusion of i nmol/ 1 glucagon for 10 rain during 100 nmol/1 exendin (9-39) infusion caused an increase in insulin release similar to the increase caused by i nmol/1 glucagon during the vehicle infusion; the degree of increase in ZAIRI from the preceding basal level (mean of 13-and 15-min values) during the exendin (9-39) infusion was 93.1 + 9.6 % compared to that of the control study.
On the other hand, insulin release caused by 0.3 nmol/1 GLP-1 during the 100 nmol/1 exendin (9-39) infusion was clearly less than that caused by 0.3nmol/1 GLP-1 during the vehicle infusion ( Fig. 1 B) ; the degree of increase in ZAIRI from the preceding basal level (mean of 13-and 15-min values) during the exendin (9-39) infusion was 45.3 + 3.7 % compared to that of the control study.
Discussion
In the present study, an antagonist of GLP-1, exendin (9-39), clearly inhibited 0.3 nmol/1 GLP-l-induced insulin release, but elicited no significant effects on 1 nmol/1 glucagon-induced insulin release from the isolated perfused rat pancreas. These results indicate that glucagon stimulates insulin release mainly through glucagon receptors but not GLP-1 receptors on islet beta cells. In other words, if there were no glucagon receptors on beta cells [17] and glucagon stimulates insulin release through GLP-1 receptors, the insulin release caused by 1 nmol/1 glucagon should be inhibited more clearly than that by 0.3 nmol/1 GLP-1. A similar result has been reported in an in vivo study using fasted dogs [18] . In our direct comparison of the insulinotropic activity of glucagon superfamily-peptides, the half-maximum effective dose (EDs0) for glucagon was 25 times greater than that for GLP-1 (2.7 nmol/1 and 50 pmol/1, respectively) [19] , while the binding of 125I-GLP-1 to GLP-1 receptor-transfected COS cells was inhibited to only 50 % by 1 ~mol/1 glucagon [20] . These results also support the conclusion of the present study.
In this study, 100 nmol/1 exendin (9-39) itself inhibited insulin release. This inhibition has been found to be dose dependent (unpublished observation). This suggests that beta-cell GLP-1 receptors in this study may in some way be activated leading to elevated basal insulin release which could then be counteracted by the antagonist. Alternatively, exendin (9-39) might modulate insulin release through other direct or indirect mechanisms. It will be interesting to study this in the future.
